Friday, June 24, 2022

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Finds a Bid on Interest in Psoriasis Treatment

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a micro-cap name that has been on quite a roller-coaster ride so far in 2017. After being the bell of the ball in February, soaring over 300% in just a matter of days mid-way through the month, the stock struggled in March, giving up those gains and more recently struggling to beat a consistently domineering offer.

Part of the issue may be a lack of recent catalysts. In answer to that possibility, the company just announced it has received expressions of interest from the scientific and medical communities worldwide as a result of its recently announced positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. The company added in that release that it plans to launch a more in-depth study of the cream next year. The stock reacted well to the news, popping back above the $1/share level on strong volume.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) bills itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.

OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.

All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, wile its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.

Find out when $OWCP stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

According to the company’s recent release, OWCP previously reported trial results and concluded that post-application of OWC’s unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis. “These promising results have led the Company to expand the size and scope of its clinical study and has led directly to OWC’s receipt of continuing inquiries and expressions of interest from researchers world-wide for more information on the cannabinoid-based topical cream for treatment of psoriasis and our product’s anticipated availability for use in the market.”

That leads to the meat of the issue: A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease.

Mr. Ziv Turner, OWC’s, Managing Director, commented, “As soon as we announced the  efficacy results  of our pre-clinical psoriasis treatment, OWC has continued to receive active inquiries from a variety of leading international scientific institutions in Countries like Germany, the Czech Republic,  Hungary and more,   that adopted or about to adopt MMJ bills. We are currently in negotiations for scientific and marketing cooperation agreements. In addition, we realistically expect product readiness for our topical cream in early Q3 2017 and, subject to regulatory approvals, federal and states laws we will be able to offer our topical cream to those who suffer from psoriasis.”

Now commanding a market cap of $139.1M, OWCP has about $90K in cash on the books as of its last reported quarterly financials. However, the company received financing of $1.6M as reported in a recent 8K filing. Hence, we presume some portion of that is still ammo in the coffers. The company is pre-revenue at this point. As more color becomes clear on the name, we will review the situation and update our take. For continuing coverage on shares of $OWCP stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles